Skip to main content

Lewis J. Geffen

Member / Co-chair, Life Science Practice and Co-chair, Venture Capital & Emerging Companies Practice

[email protected]



Lewis is a corporate and licensing attorney focused on the life sciences, with decades of experience helping companies in the sector tackle strategic issues and complete complicated transactions. He is the go-to outside lawyer for preeminent biotechnology, pharmaceutical, medical device, and medtech companies, shepherding them through financing and licensing deals that fund drug development.

Lewis serves as Co-chair of Mintz's Venture Capital & Emerging Companies and Life Science practice groups and has over 25 years of experience representing biotechnology, pharmaceutical, medical device and medtech companies in all aspects of their business and legal affairs. Lewis serves as principal outside or general counsel to leading life science companies, advising management and directors as these companies raise capital, in-license and acquire technology and assets, and then collaborate or partner with others. In addition to day-to-day corporate counseling and strategic advice to his clients, Lewis regularly advises on a variety of major domestic and international business transactions, including venture capital and other private financings, technology licensing, mergers and acquisitions, strategic alliances, and public offerings.


  • Harvard Law School (JD)
  • University of Massachusetts - Amherst (BA)


Venture Financings

  • Aura Biosciences in its $30M financing to advance the clinical development of its Ocular Melanoma treatment
  • Ysios Capital, Sofinnova Ventures, INKEF Capital and Sectoral Asset Management in the $50M Series B financing of BioClin Therapeutics, Inc.
  • Spero Therapeutics in its $51.7M financing to advance its pipeline of antibacterials focused on drug-resistant bacterial infections
  • Synlogic in its $42M, $40M, $30M and $42M financings to develop “living therapeutics”
  • Macrolide Pharmaceuticals in its $22M Series A financing to develop novel antibiotics
  • Opsonix in its $8M Series A financing to develop a broad spectrum pathogen-extracting therapy
  • Venture investors in the $21 Series B financing of Aura Biosciences, to treat ocular melanoma
  • RA Capital in numerous venture financings, including Arvinas, Cidara Therapeutics, G1 Therapeutics and White Swell Medical
  • MVM Life Science Partners in numerous venture financings, including AccuVein, BioTheranostics, Zipline Medical, Cheetah Medical and Solx
  • Merck Research and Licensing (MRL) Ventures in several financings, including RaNA Therapeutics and miRagen Therapeutics

Collaborations, Alliances and License Agreements

  • Spero Therapeutics in its collaboration with Everest Medicines to develop and commercialize SPR206 , an IV-administered gram negative antibiotic product candidate in Greater China, South Korea, and certain Southeast Asian countries
  • Synlogic in its global R&D collaboration with AbbVie to develop novel synthetic medicines to treat inflammatory bowel disease
  • Macrolide Pharmaceuticals in its agreement with Cempra to develop a synthetic manufacturing  process for solithromycin
  • Biogen Idec in its collaboration with Ataxion to develop drugs to treat hereditary ataxias
  • Amorsa Therapeutics in its research, option and license agreement with Janssen Pharmaceuticals, to develop novel ketamine-derived drugs for treatment-resistant depression
  • Spero Therapeutics in its license with Meiji Pharmaceuticals, its acquisition of worldwide rights to VXc-486/VXc-100 antibacterial compounds from Vertex Pharmaceuticals, and its acquisition of next generation antibacterial candidates from Pro Bono Bio Ltd
  • Paratek Pharmaceuticals in its $485M global collaboration with Novartis
  • Numerous foundational in-licenses from leading universities, hospitals and institutions, including Harvard, MIT, Boston University, Case Western, Michigan, Einstein College, MGH, Tufts, University of Florida, others

M&A and Public Offerings

  • Spero Therapeutics in its $88M Initial Public Offering and $75M follow-on public offering 
  • Synlogic in its IPO by way of a reverse merger with Mirna Therapeutics, Inc.
  • Synlogic in its $50M follow on public offering
  • AFT Pharmaceuticals in its $33M Initial Public Offering
  • Beacon Endoscopic in its sale to Covidien

Recognition & Awards

  • Recognized by The Legal 500 United States as “a well-known life sciences expert” for Venture Capital and Emerging Companies (2014)
  • Recommended by The Legal 500 United States for Venture Capital and Emerging Companies (2013 – 2017)
  • Martindale-Hubbell AV Preeminent


Viewpoint General
Section 141(d) of the Delaware General Corporations Law (DGCL) allows the certificate of incorporation (COI) of a Delaware corporation to confer upon one or more directors voting powers greater than or less than those of other directors, thus resulting in “disproportionate voting” rights amongst the Directors.



LSX World Congress USA

Convene - One Boston Place l Boston, MA